Does the media prefer ATRA or ORIC?

In the previous week, Oric Pharmaceuticals had 11 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 18 mentions for Oric Pharmaceuticals and 7 mentions for Atara Biotherapeutics. Oric Pharmaceuticals' average media sentiment score of 0.59 beat Atara Biotherapeutics' score of -0.33 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Oric Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ATRA or FATE?

In the previous week, Fate Therapeutics had 3 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 10 mentions for Fate Therapeutics and 7 mentions for Atara Biotherapeutics. Fate Therapeutics' average media sentiment score of 0.48 beat Atara Biotherapeutics' score of -0.33 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Fate Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to CLLS or ATRA?

In the previous week, Atara Biotherapeutics had 4 more articles in the media than Cellectis. MarketBeat recorded 7 mentions for Atara Biotherapeutics and 3 mentions for Cellectis. Cellectis' average media sentiment score of 0.78 beat Atara Biotherapeutics' score of -0.33 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ATRA or SABS?

In the previous week, SAB Biotherapeutics had 14 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 21 mentions for SAB Biotherapeutics and 7 mentions for Atara Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.33 beat Atara Biotherapeutics' score of -0.33 indicating that SAB Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SAB Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MYGN or ATRA?

In the previous week, Myriad Genetics had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 9 mentions for Myriad Genetics and 7 mentions for Atara Biotherapeutics. Myriad Genetics' average media sentiment score of 0.54 beat Atara Biotherapeutics' score of -0.33 indicating that Myriad Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Atara Biotherapeutics (ATRA) Competitors

$8.22 -0.29 (-3.41%)

As of 02:11 PM Eastern

Compare

ATRA vs. ORIC, FATE, CLLS, SABS, and MYGN

Should you buy Atara Biotherapeutics stock or one of its competitors? Atara Biotherapeutics's main competitors and comparable companies include Oric Pharmaceuticals (ORIC), Fate Therapeutics (FATE), Cellectis (CLLS), SAB Biotherapeutics (SABS), and Myriad Genetics (MYGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Atara Biotherapeutics (NASDAQ:ATRA) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Atara Biotherapeutics presently has a consensus price target of $9.50, indicating a potential upside of 15.57%. Oric Pharmaceuticals has a consensus price target of $19.45, indicating a potential upside of 40.42%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Oric Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Oric Pharmaceuticals' return on equity of -35.35% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-71.11%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

Atara Biotherapeutics has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.61	$32.69M	-$0.67	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

In the previous week, Oric Pharmaceuticals had 11 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 18 mentions for Oric Pharmaceuticals and 7 mentions for Atara Biotherapeutics. Oric Pharmaceuticals' average media sentiment score of 0.59 beat Atara Biotherapeutics' score of -0.33 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Oric Pharmaceuticals beats Atara Biotherapeutics on 10 of the 15 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Fate Therapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Atara Biotherapeutics has a net margin of -269.42% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-71.11%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

Atara Biotherapeutics has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market.

In the previous week, Fate Therapeutics had 3 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 10 mentions for Fate Therapeutics and 7 mentions for Atara Biotherapeutics. Fate Therapeutics' average media sentiment score of 0.48 beat Atara Biotherapeutics' score of -0.33 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fate Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Atara Biotherapeutics has higher revenue and earnings than Fate Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.61	$32.69M	-$0.67	N/A
Fate Therapeutics	$6.32M	46.97	-$136.32M	-$1.09	N/A

Atara Biotherapeutics presently has a consensus price target of $9.50, suggesting a potential upside of 15.57%. Fate Therapeutics has a consensus price target of $5.90, suggesting a potential upside of 131.83%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Fate Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Fate Therapeutics beats Atara Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Cellectis?

Cellectis (NASDAQ:CLLS) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Atara Biotherapeutics has higher revenue and earnings than Cellectis. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.93	-$67.59M	-$0.65	N/A
Atara Biotherapeutics	$120.77M	0.61	$32.69M	-$0.67	N/A

Cellectis has a beta of 2.91, suggesting that its stock price is 191% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market.

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cellectis has a net margin of -102.34% compared to Atara Biotherapeutics' net margin of -269.42%. Atara Biotherapeutics' return on equity of -79.12% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Atara Biotherapeutics	-269.42%	-79.12%	-71.11%

Cellectis presently has a consensus target price of $7.00, suggesting a potential upside of 124.36%. Atara Biotherapeutics has a consensus target price of $9.50, suggesting a potential upside of 15.57%. Given Cellectis' stronger consensus rating and higher probable upside, analysts plainly believe Cellectis is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Atara Biotherapeutics had 4 more articles in the media than Cellectis. MarketBeat recorded 7 mentions for Atara Biotherapeutics and 3 mentions for Cellectis. Cellectis' average media sentiment score of 0.78 beat Atara Biotherapeutics' score of -0.33 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cellectis beats Atara Biotherapeutics on 11 of the 17 factors compared between the two stocks.

How does Atara Biotherapeutics compare to SAB Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Atara Biotherapeutics currently has a consensus target price of $9.50, suggesting a potential upside of 15.57%. SAB Biotherapeutics has a consensus target price of $12.00, suggesting a potential upside of 220.43%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe SAB Biotherapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Atara Biotherapeutics has higher revenue and earnings than SAB Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.61	$32.69M	-$0.67	N/A
SAB Biotherapeutics	$1.32M	258.15	$13.27M	-$1.30	N/A

SAB Biotherapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. SAB Biotherapeutics' return on equity of -6.74% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-71.11%
SAB Biotherapeutics	N/A	-6.74%	-6.06%

In the previous week, SAB Biotherapeutics had 14 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 21 mentions for SAB Biotherapeutics and 7 mentions for Atara Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.33 beat Atara Biotherapeutics' score of -0.33 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
SAB Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Atara Biotherapeutics has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Summary

SAB Biotherapeutics beats Atara Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Myriad Genetics?

Myriad Genetics (NASDAQ:MYGN) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Myriad Genetics has a net margin of -13.96% compared to Atara Biotherapeutics' net margin of -269.42%. Myriad Genetics' return on equity of -16.09% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Atara Biotherapeutics	-269.42%	-79.12%	-71.11%

In the previous week, Myriad Genetics had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 9 mentions for Myriad Genetics and 7 mentions for Atara Biotherapeutics. Myriad Genetics' average media sentiment score of 0.54 beat Atara Biotherapeutics' score of -0.33 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Atara Biotherapeutics has lower revenue, but higher earnings than Myriad Genetics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.36	-$365.90M	-$1.19	N/A
Atara Biotherapeutics	$120.77M	0.61	$32.69M	-$0.67	N/A

Myriad Genetics presently has a consensus target price of $5.38, indicating a potential upside of 73.67%. Atara Biotherapeutics has a consensus target price of $9.50, indicating a potential upside of 15.57%. Given Myriad Genetics' higher probable upside, equities research analysts plainly believe Myriad Genetics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Myriad Genetics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market.

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Myriad Genetics beats Atara Biotherapeutics on 10 of the 15 factors compared between the two stocks.

Get Atara Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATRA vs. The Competition

Export

Metric	Atara Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$74.06M	$3.70B	$6.98B	$13.02B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-6.97	10.43	269.27	25.24
Price / Sales	0.61	1,288.46	597.12	100.97
Price / Cash	1.90	103.01	70.53	50.75
Price / Book	-1.54	17.49	13.06	6.33
Net Income	$32.69M	-$13.32M	$3.45B	$347.70M
7 Day Performance	-2.72%	1.33%	0.91%	0.94%
1 Month Performance	2.24%	1.20%	1.59%	0.90%
1 Year Performance	-29.86%	55.62%	67.34%	20.38%

Atara Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATRA Atara Biotherapeutics	1.841 of 5 stars	$8.22 -3.4%	$9.50 +15.6%	-29.8%	$74.06M	$120.77M	N/A	330	Earnings Report
ORIC Oric Pharmaceuticals	2.3667 of 5 stars	$10.60 -4.2%	$19.27 +81.8%	+39.6%	$1.15B	N/A	N/A	80	Analyst Revision
FATE Fate Therapeutics	3.1311 of 5 stars	$2.50 +2.0%	$5.13 +105.0%	+123.0%	$285.57M	$6.65M	N/A	550	News Coverage Earnings Report Analyst Forecast Gap Up
CLLS Cellectis	2.3661 of 5 stars	$2.75 flat	$7.00 +154.5%	+14.0%	$275.93M	$79.59M	N/A	290	Gap Up
SABS SAB Biotherapeutics	2.6887 of 5 stars	$3.79 +6.2%	$12.00 +216.6%	+74.4%	$272.98M	$1.32M	N/A	140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATRA) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, FATE, CLLS, SABS, and MYGN

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Summary

How does Atara Biotherapeutics compare to Fate Therapeutics?

Summary

How does Atara Biotherapeutics compare to Cellectis?

Summary

How does Atara Biotherapeutics compare to SAB Biotherapeutics?

Summary

How does Atara Biotherapeutics compare to Myriad Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, FATE, CLLS, SABS, and MYGN

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Do analysts prefer ATRA or ORIC?

Is ATRA or ORIC more profitable?

Which has more volatility and risk, ATRA or ORIC?

Which has better valuation & earnings, ATRA or ORIC?

Does the media prefer ATRA or ORIC?

Do insiders and institutionals believe in ATRA or ORIC?

Summary

How does Atara Biotherapeutics compare to Fate Therapeutics?

Is ATRA or FATE more profitable?

Which has more risk & volatility, ATRA or FATE?

Does the media refer more to ATRA or FATE?

Do insiders & institutionals hold more shares of ATRA or FATE?

Which has better valuation & earnings, ATRA or FATE?

Do analysts prefer ATRA or FATE?

Summary

How does Atara Biotherapeutics compare to Cellectis?

Which has better earnings & valuation, CLLS or ATRA?

Which has more risk & volatility, CLLS or ATRA?

Do insiders and institutionals hold more shares of CLLS or ATRA?

Is CLLS or ATRA more profitable?

Do analysts recommend CLLS or ATRA?

Does the media refer more to CLLS or ATRA?

Summary

How does Atara Biotherapeutics compare to SAB Biotherapeutics?

Do insiders & institutionals hold more shares of ATRA or SABS?

Do analysts prefer ATRA or SABS?

Which has stronger valuation and earnings, ATRA or SABS?

Is ATRA or SABS more profitable?

Does the media prefer ATRA or SABS?

Which has more risk & volatility, ATRA or SABS?

Summary

How does Atara Biotherapeutics compare to Myriad Genetics?

Is MYGN or ATRA more profitable?

Does the media favor MYGN or ATRA?

Which has higher valuation & earnings, MYGN or ATRA?

Do analysts recommend MYGN or ATRA?

Which has more risk & volatility, MYGN or ATRA?

Do insiders and institutionals have more ownership in MYGN or ATRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools